EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$122.65M
• Dividend Yield: 1.44%
• Average Volume (3M): 64.50K
• Price to Earnings (P/E): 17.8
• Beta (1Y): 0.26
• Revenue Growth: 0.65%
• EPS Growth: -9.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 47,173,200
• 10 Day Avg. Volume: 39,869
• 30 Day Avg. Volume: 64,495
• PEG Ratio: -2.57
• Price to Book (P/B): 3.85
• Price to Sales (P/S): 1.62
• P/FCF Ratio: 26.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.50
• Price Target Upside: -9.75% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: AU$3.00 ▲(8.30% Upside)

EZZ Life Science Holdings Ltd. scores well due to strong financial performance and positive technical indicators. The company's profitability and solid balance sheet are significant strengths, while the technical analysis suggests bullish momentum. Valuation is reasonable but not a standout factor.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Ltd. (EZZ) is a health and wellness company focused on developing, manufacturing, and distributing innovative dietary supplements and health products. Operating primarily in the nutraceutical sector, EZZ offers a range of products aimed at enhancing health and well-being, including supplements that support immune health, energy levels, and overall vitality. The company emphasizes research and development to create high-quality formulations that cater to the evolving needs of health-conscious consumers.

How the Company Makes Money

EZZ generates revenue through the sale of its dietary supplements and health products, which are marketed both online and through retail partnerships. The company employs a multi-channel distribution strategy, leveraging e-commerce platforms and traditional retail outlets to reach a broad audience. Key revenue streams include direct-to-consumer sales via their website and partnerships with health and wellness retailers. Additionally, EZZ may engage in strategic collaborations with other companies in the health sector to expand its product offerings and market reach, contributing to its overall earnings.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

EZZ Life Science Holdings Ltd. exhibits strong financial health with significant revenue and profit growth. The income statement reflects an impressive 78.9% revenue increase, and the company maintains a high gross profit margin of 74.2%. The balance sheet is robust, supported by a low debt-to-equity ratio of 0.01 and a strong ROE of 32.7%. Cash flow metrics are solid, with a 46.6% increase in free cash flow, indicating efficient cash management.

Income Statement

EZZ Life Science Holdings Ltd. demonstrates strong revenue growth, with a 78.9% increase in total revenue from 2023 to 2024. The gross profit margin is robust at 74.2%, indicating efficient cost management. Net profit margin stands at 10.5%, showing healthy profitability, though there's room for improvement in converting revenue to net income. EBIT and EBITDA margins are solid at 14.6% and 15.6%, respectively, reflecting operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.01, showcasing a conservative leverage strategy. Return on Equity (ROE) is strong at 32.7%, indicating effective use of shareholders' equity. The equity ratio is high at 83.5%, highlighting financial stability and low financial risk. Overall, the balance sheet reflects a strong financial position with minimal debt.

Cash Flow

EZZ Life Science Holdings Ltd. shows a significant increase in free cash flow, with a growth rate of 46.6% from the previous year. The operating cash flow to net income ratio is 0.88, indicating efficient cash generation relative to reported earnings. The free cash flow to net income ratio is 0.82, suggesting that the company's operations are generating ample cash relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.87M	66.87M	66.44M	37.14M	15.02M	22.29M
Gross Profit	49.72M	49.72M	50.95M	27.20M	7.51M	12.46M
EBITDA	10.08M	11.10M	10.38M	5.09M	1.90M	2.87M
Net Income	6.73M	6.73M	6.96M	3.63M	1.31M	2.03M
Balance Sheet
Total Assets	33.96M	33.96M	25.55M	17.64M	14.27M	12.04M
Cash, Cash Equivalents and Short-Term Investments	20.85M	20.85M	19.02M	13.83M	10.46M	8.85M
Total Debt	304.49K	304.49K	123.86K	478.59K	104.57K	79.01K
Total Liabilities	5.87M	5.87M	4.23M	3.06M	2.88M	1.93M
Stockholders Equity	28.09M	28.09M	21.32M	14.58M	11.39M	10.11M
Cash Flow
Free Cash Flow	4.13M	4.09M	5.73M	3.91M	1.89M	237.42K
Operating Cash Flow	4.37M	4.35M	6.14M	4.01M	1.90M	253.53K
Investing Cash Flow	-546.93K	-546.93K	-441.17K	-101.78K	-13.18K	-16.12K
Financing Cash Flow	-2.17M	-2.17M	-582.45K	-761.72K	-277.36K	5.44M

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Positive. The current price of 2.77 is above the 20-day moving average (MA) of 2.39, above the 50-day MA of 2.34, and above the 200-day MA of 2.01, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 66.73 is Neutral, neither overbought nor oversold. The STOCH value of 85.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	74 Outperform	AU$122.65M	17.83	27.24%	1.44%	0.65%	-9.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATH	46 Neutral	$130.50M	―	-42.68%	―	―	63.46%
RCE	45 Neutral	AU$117.12M	―	―	―	―	0.66%
ATX	45 Neutral	$82.09M	―	-41.60%	―	―	4.07%
IMU	43 Neutral	$122.77M	―	-83.09%	―	―	55.94%
ALA	40 Underperform	AU$113.72M	―	-47.98%	―	700.00%	26.88%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Reports Strong Q4 Growth and Strategic Expansions

EZZ Life Science Holdings Ltd. has reported significant growth and strategic advancements in its quarterly activity report for Q4 FY25. The company successfully launched its EZZDAY brand in the United States, expanded its Southeast Asia distribution through a new agreement with ROFA Enterprises, and increased its presence in Australian pharmacies via a partnership with Direct Chemist Outlet. EZZ also engaged the University of Sydney for research on bone health supplements and reported strong financial performance with a 46% increase in customer receipts and a positive cash inflow. These developments position EZZ to capitalize on the growing demand for health supplements and maintain its competitive edge in the global health and wellness sector.

EZZ Life Science Holdings: Strategic Investor Communication

EZZ Life Science Holdings Ltd. has released a presentation document outlining its current position and future outlook. The document emphasizes the company’s caution regarding forward-looking statements and advises investors to conduct their own assessments. This release highlights the company’s commitment to transparency and careful communication with its stakeholders, reflecting a strategic approach to managing investor relations and market expectations.

EZZ Life Science Expands into US Market with EZZDAY Launch

EZZ Life Science Holdings Limited has launched its US-focused brand, EZZDAY, marking a significant step in its international expansion strategy. The launch includes FDA-registered health supplements tailored for the US market, supported by local manufacturing to meet consumer preferences and ensure supply chain resilience. The company has initiated sales through a Shopify store, with plans to expand to Amazon and engage in influencer marketing to boost brand awareness. This strategic entry into the US, one of the largest health supplement markets, aims to establish a sustainable presence and capitalize on the growing demand in key health categories.

EZZ Life Science Holdings Announces Dividend Distribution

EZZ Life Science Holdings Ltd. has announced a dividend distribution of AUD 0.02 per ordinary fully paid share, covering the six-month period ending December 31, 2024. The ex-dividend date is set for May 16, 2025, with the record date on May 19, 2025, and payment scheduled for June 17, 2025. This announcement reflects the company’s financial health and commitment to returning value to shareholders, potentially strengthening its market position and investor confidence.

EZZ Life Science Declares Interim Dividend for 2024

EZZ Life Science Holdings Limited has announced a fully franked interim dividend of $0.020 per share for the half year ending 31 December 2024. This decision reflects the company’s commitment to rewarding shareholders and may enhance investor confidence. The dividend will be paid on 17 June 2025, with the ex-dividend date set for 16 May 2025 and the record date on 19 May 2025.